NEW YORK (GenomeWeb) – Three years after Regeneron Pharmaceuticals began sequencing human exomes on a large scale and analyzing them along with electronic health records, the effort has started to bear fruit in the form of new drug targets and additional insights into existing ones.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.